BamSEC and AlphaSense Join Forces
Learn More

Quince Therapeutics Inc.

NASDAQ: QNCX    
Share price (8/15/25): $1.69    
Market cap (8/15/25): $90.8 million
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.2
from 8-K 17 pages Form of Warrant to Purchase Shares of Common Stock or Pre-Funded Warrants
12/34/56
EX-4.1
from 8-K 15 pages Form of Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-4.3
from 10-K 4 pages Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.4
from S-3 55 pages Quince Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [], 20__ Debt Securities
12/34/56
EX-4.1
from 8-K 52 pages Rights Agreement April 5, 2023
12/34/56
EX-4.8
from POSASR 55 pages Cortexyme, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 20__ Debt Securities
12/34/56
EX-4.3
from 10-K 6 pages Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.8
from S-3ASR 44 pages Cortexyme, Inc. and , as Trustee, Indenture Dated as of Debt Securities Reconciliation and Tie Between Trust Indenture Act of 1939, as Amended, and the Indenture
12/34/56
EX-4.3
from 10-K 8 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.1
from 8-K 6 pages Form of Stock Purchase Agreement
12/34/56
EX-4.1
from S-1/A 2 pages Indenture or similar
12/34/56
EX-4.2
from S-1 87 pages Cortexyme, Inc. Amended and Restated Investors’ Rights Agreement
12/34/56
EX-4.2
from DRS 87 pages Cortexyme, Inc. Amended and Restated Investors’ Rights Agreement
12/34/56